Literature DB >> 7055097

Predictability of immunologic phenotype by morphologic criteria in diffuse aggressive non-Hodgkin's lymphomas.

E S Jaffe, J A Strauchen, C W Berard.   

Abstract

Diffuse aggressive non-Hodgkin's lymphomas are immunologically and morphologically heterogeneous. Morphologic subclassifications have been proposed with a presumptive relationship to immunologic phenotype. Six histologic types were studied, four of presumed follicular origin (large cleaved, large non-cleaved, mixed follicular center cell, and blastic) and two of presumed nonfollicular origin (pleomorphic pyroninophilic and pleomorphic convoluted). Two of these follicular subtypes were found to be associated with the frequent presence of B-cell markers; large non-cleaved, six of seven; and blastic, four of six. However, four of nine T-cell lymphomas were misclassified as lesions of follicular center cell type, indicating the difficulty of distinguishing some convoluted cells of T-cell lymphoma from irregularly cleaved cells of follicular lymphoma. Pleomorphic pyroninophilic or B-immunoblastic morphology was associated with B-cell markers in only two of six cases; two additional cases had T-cell markers, one had histiocytic markers and in one case, no markers were demonstrable. Thus, this morphology may reflect a common pathway of transformed lymphoid cells. Some cases of T-cell origin could be recognized by the striking pleomorphic convoluted histology (three of five cases) but morphologic overlap with pleomorphic B-cell tumors, particularly transformed nodular lymphomas, posed a problem. This histopathologic subclassification correctly predicted immunologic phenotype in only 61% of cases, suggesting that in diffuse non-Hodgkin's lymphomas, histologic appearance alone may not be a reliable indicator of immunologic surface markers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7055097     DOI: 10.1093/ajcp/77.1.46

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Application of quantifiable criteria in the Lukes and Collins classification of non-Hodgkin's lymphomas.

Authors:  H Schultz; J Ersbøll
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 2.  Current views on the diagnosis of lymphomas by surface and cytoplasmic markers.

Authors:  R E Lewis; W W Johnson; J M Cruse
Journal:  Surv Immunol Res       Date:  1982

3.  Immunohistologic cellular phenotypes of lymphoproliferative disorders. Comprehensive evaluation of 564 cases including 257 non-Hodgkin's lymphomas classified by the International Working Formulation.

Authors:  R R Tubbs; A Fishleder; R A Weiss; R A Savage; B A Sebek; J K Weick
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

4.  The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases.

Authors:  S E Shackney; A M Levine; R I Fisher; P Nichols; E Jaffe; W H Schuette; R Simon; C A Smith; S J Occhipinti; J W Parker
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

5.  Clonality of T cell and phenotypically undefined lymphoid neoplasms: the value of genotypic analyses.

Authors:  E Hodges; G N Stacey; W M Howell; D B Jones; J L Smith
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

6.  Cytodiagnosis of non-Hodgkin's lymphoma. A morphological analysis of 215 biopsy proven cases.

Authors:  P van Heerde; D Go; M A Koolman-Schellekens; J L Peterse
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

7.  SIg-E- ("null-cell") non-Hodgkin's lymphomas. Multiparametric determination of their B- or T-cell lineage.

Authors:  D M Knowles; L Dodson; J S Burke; J M Wang; F Bonetti; P G Pelicci; F Flug; R Dalla-Favera; C Y Wang
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

Review 8.  Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia.

Authors:  D M Knowles
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

9.  EBM/11 reactivity in malignant histiocytosis.

Authors:  P M Kelly; M McGovern; K C Gatter; J M Theaker; J O McGee
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.